Lamotrigine and side effects
Another headache
Citation Manager Formats
Make Comment
See Comments

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
For approximately 65 million people in the world with epilepsy, antiepileptic drugs (AEDs) are the mainstay of treatment.1 Lamotrigine (LTG) is a nonenzyme inducing AED with favorable pharmacokinetics, approved for use by the Food and Drug Administration (FDA) in epilepsy as well as bipolar disorder. From May 2009 to April 2010, approximately 9 million prescriptions were dispensed from outpatient pharmacies.2 In epilepsy, it has proven to be effective in a wide variety of seizure types and patient groups (2 years of age and older), with clinical applicability in focal seizures and in generalized seizures associated with both genetic epilepsy and the Lennox-Gastaut syndrome. Both the efficacy and safety profile of LTG have been defined by numerous clinical studies.3 Compared with other first-line AEDs, LTG is well tolerated with little sedation or cognitive impairment, weight neutrality, and a favorable psychotropic profile. A recent large randomized comparative effectiveness trial found LTG as the drug of first choice for patients with presumed partial (focal) epilepsy.4 Since efficacy among AEDs does not differ for common epilepsy syndromes, tolerability becomes a critical factor in drug selection.3
Adverse effects have long been recognized with all AEDs.5 Upon its release in 1994, rash hampered the use of LTG. A black box warning in the prescribing information reflected the possibility of serious rash …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Disputes & Debates: Rapid online correspondence
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within the last 8 weeks.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.